Novartis AG Common Stock (NVS)
R&D Expenses
$11.28B
TTM · Period ending: · USD
NVS R&D Expenses
Latest reported$11.28Bperiod ending
Latest reported$11.28Bperiod ending
NVS R&D Expenses ($2.84B → $11.28B)
Annual R&D Expenses
High-resolution chart · PNG
NVS r&d expenses history
Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expenses (USD) |
|---|---|
| 10,741,727,000 | |
| 10,022,000,000 | |
| 11,371,000,000 | |
| 9,172,000,000 | |
| 8,641,000,000 | |
| 8,980,000,000 | |
| 9,402,000,000 | |
| 8,489,000,000 | |
| 8,389,000,000 | |
| 9,039,000,000 | |
| 8,935,000,000 | |
| 9,086,000,000 | |
| 9,071,000,000 | |
| 8,588,000,000 | |
| 9,583,000,000 | |
| 9,070,000,000 | |
| 7,469,000,000 | |
| 7,217,000,000 | |
| 6,430,000,000 | |
| 5,321,000,000 | |
| 4,797,000,000 | |
| 4,152,000,000 | |
| 3,729,000,000 | |
| 2,843,000,000 | |
| 2,528,000,000 | |
| 2,885,000,000 | |
| 2,666,000,000 | |
| 2,838,663,000 |